A new review from the ESTRO CNS Focus Group explores the role of reirradiation in recurrent brain tumours, highlighting opportunities, challenges and future research needs.
🔗 Read the publication: doi.org/10.1016/j.ct...

A new review from the ESTRO CNS Focus Group explores the role of reirradiation in recurrent brain tumours, highlighting opportunities, challenges and future research needs.
🔗 Read the publication: doi.org/10.1016/j.ct...
Biohaven Showcases Promising BHV-1530 Data at EORTC-NCI-AACR Symposium 2026 #United_States #Biohaven #New_Haven #BHV-1530 #EORTC-NCI-AACR
At #EANO2026, #EORTC 2227-LEGATO trial is addressing an important question: does adding #reirradiation to lomustine improve outcomes compared with lomustine alone in #glioblastoma?
Hopefully this phase III trial will generate the evidence needed to define the role of reRT at first progression.
#EANO2026 Chair Giuseppe Minniti takes the stage to officially open the congress, kicking off a packed programme with 44 scientific sessions, poster presentations, and contributions from scientific partners such as @eortc.org
#radiotherapy #EANO #EORTC
On #WRAD2026, we're celebrating a major milestone for radiotherapy research: 1,000 patients have now been enrolled in the ReCare cohort of the EORTC-ESTRO E²-RADIatE platform 🎉
Thank you to all the patients, investigators and study teams making this possible.